NRX Pharmaceuticals (NRXP) Current Deferred Revenue (2021 - 2022)
NRX Pharmaceuticals (NRXP) posted quarterly Current Deferred Revenue of $56000.0 for Q3 2022, down 95.56% year-over-year from $1.3 million in Q3 2021, and up 194.74% quarter-over-quarter from $19000.0 in Q2 2022.
NRX Pharmaceuticals (NRXP) Current Deferred Revenue (2021 - 2022) Analysis & Trends
NRX Pharmaceuticals (NRXP) has reported Current Deferred Revenue for 2 consecutive years, with $56000.0 the latest figure, recorded in Q3 2022.
- In Q3 2022, Current Deferred Revenue fell 95.56% year-over-year to $56000.0; the TTM figure through Sep 2022 stood at $56000.0 (down 95.56% YoY), while the FY2021 annual figure was $292000.0, changed N/A from the prior year.
- Current Deferred Revenue improved to $56000.0 in Q3 2022 per NRXP's latest filing, from $19000.0 in the prior quarter.
- Across five years, Current Deferred Revenue topped out at $22.8 million in Q2 2021 and bottomed at $19000.0 in Q2 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | NRX Pharmaceuticals | 132.53 Mn | 105.83 Mn | 426,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2022 | 56,000.00 |
| Jun 30, 2022 | 19,000.00 |
| Mar 31, 2022 | 135,000.00 |
| Dec 31, 2021 | 292,000.00 |
| Sep 30, 2021 | 1.26 Mn |
| Jun 30, 2021 | 22.85 Mn |